Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00749892 · OUTCOME

Response Rate

Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer · Source last updated 2020-09-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Determined at the time of surgery or cystectomy

What was measured

The response rate is the number of patients with urothelial cancer treated with erlotinib prior to cystectomy. The response is defined as the absence of residual cancer in the surgical removed tissue (i.e., pT0). A responder is defined as a participant with the pathological stage of pT0 meaning that there is no evidence of disease.

Analysis population: two participants did not take any eroltinib and three participants stopped erlotinib early due to intolerable side effects.

Groups in this outcome

Pre-surgical Erlotinib Treatment

Erlotinib 150 mg by mouth daily for 3 weeks followed by cystectomy within 24 hours of the last dose.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Pre-surgical Erlotinib Treatment26

Reported measurements

Number of Responders
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Pre-surgical Erlotinib Treatment8Not reportedNot reportedNot reportedNot reported
Number of Non Responders
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Pre-surgical Erlotinib Treatment18Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        8
    title
    Number of Responders
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        18
    title
    Number of Non Responders
denoms
  1. counts
    1. group Id
      OG000
      value
      26
    units
    Participants
description
The response rate is the number of patients with urothelial cancer treated with erlotinib prior to cystectomy. The response is defined as the absence of residual cancer in the surgical removed tissue (i.e., pT0). A responder is defined as a participant with the pathological stage of pT0 meaning that there is no evidence of disease.
groups
  1. description
    Erlotinib 150 mg by mouth daily for 3 weeks followed by cystectomy within 24 hours of the last dose.
    id
    OG000
    title
    Pre-surgical Erlotinib Treatment
param Type
COUNT_OF_PARTICIPANTS
population Description
two participants did not take any eroltinib and three participants stopped erlotinib early due to intolerable side effects.
reporting Status
POSTED
time Frame
Determined at the time of surgery or cystectomy
title
Response Rate
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice